As discussed above, biomarkers such as PD-L1, tumor mutational burden (TMB), microsatellite instability (MSI), and tumor-infiltrating lymphocyte (TIL) density can provide important information on the responsiveness to immune checkpoint inhibitors. Here, CD274 is linked to neoplasm.